罗拉吡坦为一口服有效的长效高选择性神经激肽-1受体拮抗剂。已经被美国食品和药物管理局批准联合其他止吐药物用于预防化疗药物诱发的迟发期恶心、呕吐。罗拉吡坦具有较长的终末半衰期,对CYP3A4无诱导和抑制作用。常见的不良反应为中性粒细胞减少、呃逆、腹痛、头晕、消化不良和尿道感染等。 Lorapyrate is an orally available long-acting, highly selective neurokinin-1 receptor antagonist. Has been approved by the US Food and Drug Administration in conjunction with other antiemetics for the prevention of chemotherapy-induced late-onset nausea and vomiting. Ropitron has a longer terminal half-life, no induction and inhibition of CYP3A4. Common adverse reactions are neutropenia, hiccups, abdominal pain, dizziness, indigestion and urinary tract infections.